0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Chronic Growth Hormone Administration Does Not Suppress Endogenous Growth Hormone Secretion in Patients with Neurosecretory Growth Hormone Dysfunction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Short children who respond normally to growth hormone (GH) stimulation, but have a subnormal spontaneous secretion of GH (neurosecretory GH dysfunction, NSD) are treated with exogenous GH which might suppress their endogenous GH secretion. The effect of chronic administration of GH (8–24 months) on plasma GH responses to GHRH, clonidine and spontaneous GH secretion were studied in 17 NSD patients. The diagnosis of NSD was based on a normal GH response to clonidine ( > 10 µg/l) and an integrated concentration of (IC-GH) GH < 3.2 µg/l. The GH dose used in this study was 0.25 IU/kg three times a week in 10 patients and 0.05 IU/kg daily in 7 patients. Insulin-like growth factor I levels (nmol) increased significantly on therapy from 9.3 ± 3.8 to 24.4 ± 22.4 (p < 0.001). The GH response (µg/l) to GHRH was 20.4 ± 5.5 before treatment and 22.4 ± 6.2 on GH. Peak GH after clonidine was 22.4 ± 8.9 and 22.8 ± 8.1, respectively. There was no significant decrease in the number of GH spontaneous peaks (1.8 ± 0.7 vs. 2.0 ± 0.7, respectively) or in the area under the curve. A subcutaneous GH bolus of 0.25 IU/kg in 4 patients resulted in a GH peak of 55–82 µg/l at 3–5 h and a gradual return to basal levels at 15–20 h after GH administration. The first spontaneous GH peak appeared 26–28 h after GH injection, peak amplitude was 10–15 µg/l. Administration of a smaller subcutaneous dose 0.05 IU/kg to 7 patients resulted in a GH peak of 40 ± 10 µg/l at 4–5 h and a gradual return to basal levels at 10–12 h after GH administration. The first spontaneous GH surge was then noted within 4–7 h of GH return to basal levels. The amplitude of the first spontaneous peak was 30.5–13.0 µg/l. In conclusion, GH therapy in NSD patients on either alternate day or daily basis does not inhibit GH secretion. Four to nine h after GH disappearance, GH secretion recovers; GH recovery is dose dependent.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          1663-2818
          1663-2826
          1991
          1991
          02 December 2008
          : 35
          : 3-4
          : 95-98
          Affiliations
          aPediatric Endocrine Unit, Kaplan Hospital, Rehovot, Israel; bPediatric Endocrine Clinic, Soroka Hospital, Beer-Sheva, Israel
          Article
          181881 Horm Res 1991;35:95–98
          10.1159/000181881
          1806474
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Original Paper

          Comments

          Comment on this article